At a cash burn rate of just $1-1.5M/quarter, it's well worth finding out. According to Yahoo Finance, the company had $5.2 million in cash as of the most recent quarter, and no debt.

We raised $8.5 million earlier this year and have continued to be conservative in our cash burn rate while increasing our research and development expenses as we prepare for a larger Phase II trial. Our business model of focusing on product development without building our own infrastructure to do basic research and relying on outsourcing to the best-of-breed specialty service providers, has proven to be extremely capital efficient and a source of strategic strength in hard economic times. We finished Q2, 2010 with a cash balance of over $7.7 million. IMUC is in its strongest financial position ever, and we believe we have sufficient capital on hand to take ICT-107 through a significant portion of the planned Phase II study.

insider schreef:Maarten,


Cash burn rate :

At a cash burn rate of just $1-1.5M/quarter, it's well worth finding out. According to Yahoo Finance, the company had $5.2 million in cash as of the most recent quarter, and no debt.

artikel : http://seekingalpha.com/article/250575- ... f-the-cost" onclick="window.open(this.href);return false;

We raised $8.5 million earlier this year and have continued to be conservative in our cash burn rate while increasing our research and development expenses as we prepare for a larger Phase II trial. Our business model of focusing on product development without building our own infrastructure to do basic research and relying on outsourcing to the best-of-breed specialty service providers, has proven to be extremely capital efficient and a source of strategic strength in hard economic times. We finished Q2, 2010 with a cash balance of over $7.7 million. IMUC is in its strongest financial position ever, and we believe we have sufficient capital on hand to take ICT-107 through a significant portion of the planned Phase II study.

artikel : http://www.imuc.com/imuc-09-03-2010" onclick="window.open(this.href);return false;

jnn1 schreef:Heb ze op Keytrade Bank gevonden, maar deze raden de aankoop via deze markt af: geen zekerheid.

jnn1 schreef:Hallo,

Bij wie kan je deze aandelen aankopen? Ik ben klant bij Keytrade, Rabobank en Deutsche Bank.

Ze zijn in één week 15% gestegen...


Alvast bedankt.

Immunocellular Therapeutics (IMUC.OB) -- On Thursday, Summer Street Research initiated coverage on the company with a Buy rating and price target of $8. While we feel the new price target may be a little high, there is definite upside at IMUC. This is particularly true if the firm announces an uplisting to the AMEX as previously reported. Once they are on a bigger exchange, the stock will get more attention from brokers, funds and institutionals. Their science platform is solid, their management team has shown that they can be very careful with cash management and they one of the leading candidates in the cancer immunotherapy space. A nice base has been building at the $2 mark and it should continue higher form here.

Of the patients enrolled in our Phase I study of ICT-107, 38% were still completely free of disease after 2.5 years, compared to less than 5% expected based on historical data. Additionally, the safety profile of ICT-107 is considerably better than that of Avastin

Knowing which cancer vaccines truly represent a new paradigm in the treatment of cancer is absolutely critical. The science and early clinical trial results which have been presented by ImmunoCellular at places like ASCO tell us that there is nothing small about this firm, except perhaps its current valuation.